Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM Currently up 0.25 (+0.53%) in today's trading session

2 members of Congress have disclosed 8 trades in Supernus Pharmaceuticals, Inc. (SUPN) via STOCK Act filings. The most recent disclosure was a purchase by Gilbert Cisneros on 3 March 2026. The most active traders have been Gilbert Cisneros (7) and Josh Gottheimer (1). Aggregate disclosed activity totals roughly $56K in purchases and $8K in sales (midpoint estimates from bracketed disclosure amounts).

Supernus Pharmaceuticals, Inc. is currently trading at $47.19, positioned at 54% of its 52-week range ($32.51 – $59.68).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$47.19
24h Change
+0.25 (+0.53%)
52 Week Range
$32.51$59.68
View on NASDAQ

Supernus Pharmaceuticals, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for SUPN

Select to highlight on chart
8 transactions
Compliance: 100%
Gilbert Cisneros3 Mar 20267 Apr 2026PurchaseStock$1,001 - $15,000-14.34%
Gilbert Cisneros11 Dec 202512 Jan 2026PurchaseStock$1,001 - $15,000+2.23%
Gilbert Cisneros9 Oct 202518 Nov 2025SaleStock$1,001 - $15,000N/A
Gilbert Cisneros24 Mar 20257 Apr 2025PurchaseStock$1,001 - $15,000N/A
Gilbert Cisneros13 Nov 202015 Dec 2020PurchaseStock$1,001 - $15,000N/A
Gilbert Cisneros17 Jul 202019 Aug 2020PurchaseStock$1,001 - $15,000N/A
Gilbert Cisneros1 Jun 202016 Jun 2020PurchaseStock$1,001 - $15,000N/A
Josh Gottheimer28 May 202010 Jun 2020PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$2.74B

Volume

463.34K

Beta

0.54

P/E Ratio

13.76

Fundamentals

EPS

$3.43

Div. Yield

Open

$46.30

Day Range

$46.07 — $47.49

Company Information

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ · USD
Country
US
CEO
Jack A. Khattar
IPO Date
2012-05-01

Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-relea...

Earnings

Next Report

Q2 2026

4 Aug

EPS Est.

$0.42

Rev. Est.

$205.4M

Days Until

12

Recent Quarters

Q1 20265 May
EPS$0.59
Beat 110.7%
Q4 202524 Feb
EPS$0.92
Beat 228.6%
Q3 20254 Nov
EPS$1.01
Beat 23.2%
Q2 20255 Aug
EPS$0.91
Beat 93.6%
Q1 20256 May
EPS$0.42
Beat 10.5%
Q4 202425 Feb
EPS$0.75
Beat 63.0%
Q3 20244 Nov
EPS$1.06
Beat 171.8%
Q2 20246 Aug
EPS$0.36
Beat 16.1%
Q1 20248 May
EPS$0.26
Miss 31.6%
Q4 202327 Feb
EPS$0.02
Miss 95.1%
Q3 20238 Nov
EPS$-0.29
Miss 323.1%
Q2 20238 Aug
EPS$-0.02
Miss 108.7%
Q1 20239 May
EPS$0.29
Beat 70.6%
Q4 202228 Feb
EPS$0.43
Miss 36.8%
Q3 20228 Nov
EPS$0.03
Miss 91.7%
Q2 20224 Aug
EPS$0.14
Miss 51.7%
Q1 20229 May
EPS$0.43
Beat 65.4%
Q4 202128 Feb
EPS$0.04
Miss 81.3%
Q3 20213 Nov
EPS$0.40
Beat 73.9%
Q2 20214 Aug
EPS$0.43
Beat 115.0%
Q1 20215 May
EPS$0.11
Miss 54.2%
Q4 202025 Feb
EPS$0.57
Beat 9.6%
Q3 20203 Nov
EPS$0.74
Beat 146.7%
Q2 202018 Aug
EPS$0.65
Beat 54.8%
Q1 20205 May
EPS$0.40
Beat 42.9%
Q4 201925 Feb
EPS$0.62
Beat 3.3%
Q3 20195 Nov
EPS$0.54
Miss 10.0%
Q2 20196 Aug
EPS$0.61
Beat 5.2%
Q1 20197 May
EPS$0.34
Miss 27.7%
Q4 201826 Feb
EPS$0.48
Beat 77.8%
Q3 20186 Nov
EPS$0.52
Beat 26.8%
Q2 20187 Aug
EPS$0.57
Beat 32.6%
Q1 20188 May
EPS$0.49
Beat 48.5%
Q4 201727 Feb
EPS$0.44
Beat 69.2%
Q3 20176 Nov
EPS$0.29
Beat 7.4%
Q2 20172 Aug
EPS$0.32
Beat 33.3%
Q1 20179 May
EPS$0.19
Miss 13.6%
Q4 201628 Feb
EPS$0.26
Beat 4.0%
Q4 201620 Jan
EPS$0.37
Beat 8.8%
Q2 20162 Aug
EPS$0.18
Beat 38.5%
Q1 20163 May
EPS$0.08
Miss 11.1%
Q4 20152 Mar
EPS$0.14
Beat 133.3%
Q3 20153 Nov
EPS$0.08
Beat 242.9%
Q2 20154 Aug
EPS$0.03
Beat 25.0%
Q1 20155 May
EPS$0.05
Beat 300.0%
Q4 201410 Mar
EPS$0.10
Beat 183.3%
Q3 201411 Nov
EPS$-0.20
Miss 144.4%
Q2 201411 Aug
EPS$0.06
Beat 133.3%
Q1 201412 May
EPS$-0.36
Beat 18.2%
Q4 201312 Mar
EPS$-0.39
Beat 27.8%
Q3 201312 Nov
EPS$-0.65
Beat 1.5%
Q2 201313 Aug
EPS$-0.57
Beat 14.9%
Q1 201313 May
EPS$-0.60
Beat 4.8%
Q4 201214 Mar
EPS$-0.51
Beat 30.1%
Q3 20127 Nov
EPS$-0.55
Beat 3.5%
Q2 201213 Aug
EPS$-0.60
Q2 201210 Aug
EPS$-0.61
Miss 27.1%
Q3 201131 Dec
EPS$51.38
Q2 201130 Sept
EPS$-6.10
Q1 201130 Jun
EPS$-4.63
Q4 201031 Mar
EPS$-0.80
Q3 201031 Dec
EPS$-0.62
Q3 200931 Dec
EPS$-0.59

1 politician traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

LLY

Eli Lilly and Company

74
$1185.87+22.86 (+1.97%)
Healthcare
2 politicians both hold this
Same sector: Healthcare
2 politicians
View Stock

JNJ

Johnson & Johnson

74
$259.27+3.64 (+1.42%)
Healthcare
2 politicians both hold this
Same sector: Healthcare
2 politicians
View Stock

MSFT

Microsoft Corporation

69
$381.58-8.76 (-2.24%)
Technology
2 politicians both hold this
$24M in total holdings
2 politicians
View Stock

Frequently Asked Questions about SUPN

Which members of Congress have traded SUPN?
2 members of Congress have disclosed 8 trades in Supernus Pharmaceuticals, Inc. (SUPN) under the STOCK Act. The most active traders are Gilbert Cisneros and Josh Gottheimer.
When was SUPN most recently disclosed by Congress?
The most recent SUPN disclosure was a purchase by Gilbert Cisneros on 3 March 2026.
What is the total disclosed congressional trading volume for SUPN?
Members of Congress have disclosed approximately $56K in SUPN purchases and $8K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in SUPN?
This SUPN page updates as soon as new STOCK Act disclosures are filed for Supernus Pharmaceuticals, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.